标题
Drug development in the era of precision medicine
作者
关键词
-
出版物
NATURE REVIEWS DRUG DISCOVERY
Volume 17, Issue 3, Pages 183-196
出版商
Springer Nature
发表日期
2017-12-08
DOI
10.1038/nrd.2017.226
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study
- (2017) E. Pujade-Lauraine et al. GYNECOLOGIC ONCOLOGY
- Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
- (2017) Brian G Feagan et al. LANCET
- Rare and low-frequency coding variants alter human adult height
- (2017) Eirini Marouli et al. NATURE
- Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy
- (2017) David R Corey NATURE NEUROSCIENCE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- GRIN2D Recurrent De Novo Dominant Mutation Causes a Severe Epileptic Encephalopathy Treatable with NMDA Receptor Channel Blockers
- (2016) Dong Li et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and development
- (2016) A. Yver ANNALS OF ONCOLOGY
- Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases
- (2016) George E. Fragoulis et al. Annual Review of Medicine
- Cancer immunotherapy: the beginning of the end of cancer?
- (2016) Sofia Farkona et al. BMC Medicine
- Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
- (2016) Marlon C. Rebelatto et al. Diagnostic Pathology
- A Precision Medicine Approach to Clinical Trials
- (2016) Rita Rubin JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
- (2016) Derralynn A Hughes et al. JOURNAL OF MEDICAL GENETICS
- Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
- (2016) Jacqueline A French et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension
- (2016) Praveen Surendran et al. NATURE GENETICS
- Functional characterization of somatic mutations in cancer using network-based inference of protein activity
- (2016) Mariano J Alvarez et al. NATURE GENETICS
- The cancer vaccine resurgence
- (2016) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
- (2016) Dominique P. Germain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis
- (2016) Felicia Cosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
- (2016) Frederick E. Dewey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 Mutations
- (2016) Yukiko Ihara et al. PLoS One
- Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
- (2016) Paul E. Hughes et al. TRENDS IN IMMUNOLOGY
- Common Molecular Pathways in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
- (2016) Jochen H. Weishaupt et al. TRENDS IN MOLECULAR MEDICINE
- Genetic Diagnosis Using Whole Exome Sequencing in Common Variable Immunodeficiency
- (2016) Patrick Maffucci et al. Frontiers in Immunology
- Quinidine in the treatment of KCNT1-positive epilepsies
- (2015) Mohamad A Mikati et al. ANNALS OF NEUROLOGY
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer
- (2015) K. S. Tewari et al. CLINICAL CANCER RESEARCH
- Genetic Discoveries Drive Molecular Analyses and Targeted Therapeutic Options in the Epilepsies
- (2015) Ryan S. Dhindsa et al. Current Neurology and Neuroscience Reports
- Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
- (2015) James G. Krueger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- CAR therapy: the CD19 paradigm
- (2015) Michel Sadelain JOURNAL OF CLINICAL INVESTIGATION
- Cancer immunotherapy: harnessing the immune system to battle cancer
- (2015) Yiping Yang JOURNAL OF CLINICAL INVESTIGATION
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- A roadmap for precision medicine in the epilepsies
- (2015) LANCET NEUROLOGY
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Clinical improvement in psoriasis with specific targeting of interleukin-23
- (2015) Tamara Kopp et al. NATURE
- Personalized medicine: Time for one-person trials
- (2015) Nicholas J. Schork NATURE
- The impact of low-frequency and rare variants on lipid levels
- (2015) Ida Surakka et al. NATURE GENETICS
- Identification of a large set of rare complete human knockouts
- (2015) Patrick Sulem et al. NATURE GENETICS
- The support of human genetic evidence for approved drug indications
- (2015) Matthew R Nelson et al. NATURE GENETICS
- FTO Obesity Variant Circuitry and Adipocyte Browning in Humans
- (2015) Melina Claussnitzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiepileptic Drugs—A Review
- (2015) Ram Sankaraneni et al. PEDIATRIC ANNALS
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Rare Variants in NR2F2 Cause Congenital Heart Defects in Humans
- (2014) Saeed Al Turki et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Targeted treatment of migrating partial seizures of infancy with quinidine
- (2014) David Bearden et al. ANNALS OF NEUROLOGY
- KCNT1gain of function in 2 epilepsy phenotypes is reversed by quinidine
- (2014) Carol J. Milligan et al. ANNALS OF NEUROLOGY
- Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)
- (2014) Denis Poddubnyy et al. ANNALS OF THE RHEUMATIC DISEASES
- Obesity and FTO: Changing Focus at a Complex Locus
- (2014) Y.C. Loraine Tung et al. Cell Metabolism
- Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies
- (2014) LANCET NEUROLOGY
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Synaptic, transcriptional and chromatin genes disrupted in autism
- (2014) Silvia De Rubeis et al. NATURE
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Obesity-associated variants within FTO form long-range functional connections with IRX3
- (2014) Scott Smemo et al. NATURE
- The contribution of de novo coding mutations to autism spectrum disorder
- (2014) Ivan Iossifov et al. NATURE
- Amgen and Regeneron push for a genetic renaissance in drug discovery
- (2014) Michael Eisenstein NATURE BIOTECHNOLOGY
- High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma
- (2014) Carsten Linnemann et al. NATURE MEDICINE
- Lipid lowering with PCSK9 inhibitors
- (2014) Razvan T. Dadu et al. Nature Reviews Cardiology
- Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
- (2014) David Cook et al. NATURE REVIEWS DRUG DISCOVERY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Romosozumab in Postmenopausal Women with Low Bone Mineral Density
- (2014) Michael R. McClung et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- GRIN2Amutation and early-onset epileptic encephalopathy: personalized therapy with memantine
- (2014) Tyler Mark Pierson et al. Annals of Clinical and Translational Neurology
- Dominant-negative effects ofKCNQ2mutations are associated with epileptic encephalopathy
- (2013) Gökce Orhan et al. ANNALS OF NEUROLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
- (2013) Nienke van Rooij et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression
- (2013) Y.-C. Lu et al. JOURNAL OF IMMUNOLOGY
- De novo mutations in epileptic encephalopathies
- (2013) et al. NATURE
- De novo mutations in histone-modifying genes in congenital heart disease
- (2013) Samir Zaidi et al. NATURE
- Human genetics as a foundation for innovative drug development
- (2013) Alexander Kamb et al. NATURE BIOTECHNOLOGY
- Validating therapeutic targets through human genetics
- (2013) Robert M. Plenge et al. NATURE REVIEWS DRUG DISCOVERY
- The bigger picture of FTO—the first GWAS-identified obesity gene
- (2013) Ruth J. F. Loos et al. Nature Reviews Endocrinology
- Five Years of GWAS Discovery
- (2012) Peter M. Visscher et al. AMERICAN JOURNAL OF HUMAN GENETICS
- A Single-nucleotide Polymorphism in SCN9A May Decrease Postoperative Pain Sensitivity in the General Population
- (2012) Guangyou Duan et al. ANESTHESIOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Patterns of treatment response in newly diagnosed epilepsy
- (2012) M. J. Brodie et al. NEUROLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency
- (2011) R. E. Dickinson et al. BLOOD
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation
- (2010) Kavya Rakhra et al. CANCER CELL
- Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib
- (2010) F Stegmeier et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
- (2010) Desmond Padhi et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci
- (2010) John D Reveille et al. NATURE GENETICS
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pain perception is altered by a nucleotide polymorphism in SCN9A
- (2010) F. Reimann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Common Genetic Variation and Human Traits
- (2009) David B. Goldstein NEW ENGLAND JOURNAL OF MEDICINE
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
- (2009) F. Van Goor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice
- (2008) Yimin Hua et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Translation of the Philadelphia chromosome into therapy for CML
- (2008) B. J. Druker BLOOD
- A HapMap harvest of insights into the genetics of common disease
- (2008) Teri A. Manolio et al. JOURNAL OF CLINICAL INVESTIGATION
- Genome-wide association studies: progress and potential for drug discovery and development
- (2008) Stephen F. Kingsmore et al. NATURE REVIEWS DRUG DISCOVERY
- A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci
- (2008) Ying Liu et al. PLoS Genetics
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started